Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02029430 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
A Phase 2 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02029430 is a Phase 2 study that has completed, run by ImmunityBio. The registered enrollment target is 15 participants.
The verdict
NCT02029430, a Phase 2 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
Interventions
- DRUG 50 mg/m2 aldoxorubicin
- DRUG 100 mg/m2 aldoxorubicin
- DRUG 150 mg/m2 aldoxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-04-03 |
| Est. Completion | 2016-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02029430
The ClinicalTrials.gov registry entry for NCT02029430 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 50 mg/m2 aldoxorubicin is the first listed.
NCT02029430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02029430 about?
NCT02029430 is a clinical study titled "A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma". This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
What is the current status of trial NCT02029430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2014-04-03. Estimated completion is 2016-04-25.
What interventions are being tested in trial NCT02029430?
The interventions under investigation include: 50 mg/m2 aldoxorubicin (DRUG), 100 mg/m2 aldoxorubicin (DRUG), 150 mg/m2 aldoxorubicin (DRUG).
Who is sponsoring clinical trial NCT02029430?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.